Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

<p>ORR, DCR, and BOR in patients treated with cobolimab 100, 300, or 900 mg plus dostarlimab.</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Diwakar Davar (15023480) (author)
Eará dahkkit:	Zeynep Eroglu (19276519) (author), Casilda Llácer Pérez (22053013) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Niranjan Yanamandra (22053022) (author), Srimoyee Ghosh (22053025) (author), Kathrin Jansen (22053028) (author), Arindam Dhar (15016280) (author), Theo Borgovan (22053031) (author), Angela Waszak (22053034) (author), Antoni Ribas (14837278) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Immunotherapy Antibody immunotherapy Checkpoint blockade Oncogenes & Tumor Suppressors PD-1 Skin Cancers Melanoma
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid